Stock Track | Syndax Pharmaceuticals Soars 5.01% as Analysts Maintain Bullish Stance and Raise Price Targets

Stock Track11-04

Syndax Pharmaceuticals (SNDX) stock is soaring 5.01% in Tuesday's trading session, buoyed by a series of positive analyst reports and raised price targets. The biopharmaceutical company's shares are gaining momentum as Wall Street experts reaffirm their confidence in its growth potential and strategic direction.

Leading the bullish sentiment, Barclays analyst Peter Lawson raised the firm's price target on Syndax from $19 to $22, while maintaining an Overweight rating on the shares. This upgrade reflects growing optimism about the company's prospects. Similarly, Bank of America Securities analyst Jason Zemansky reiterated a Buy rating on Syndax Pharmaceuticals, further solidifying the positive outlook.

Adding to the chorus of approval, H.C. Wainwright analyst Andres Y. Maldonado reaffirmed a Buy rating on Syndax with a price target of $40.00. This consistent positive feedback from multiple financial institutions suggests that investors are recognizing Syndax's potential for growth and success in the competitive pharmaceutical market. As the company continues to make strategic advancements, the market appears to be responding favorably to its long-term prospects.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1168376862?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-04 23:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1168376862","market":"us","top_or_hot":-1,"title":"Stock Track | Syndax Pharmaceuticals Soars 5.01% as Analysts Maintain Bullish Stance and Raise Price Targets","media":"Stock Track","content":"<p>Syndax Pharmaceuticals (SNDX) stock is soaring 5.01% in Tuesday's trading session, buoyed by a series of positive analyst reports and raised price targets. The biopharmaceutical company's shares are gaining momentum as Wall Street experts reaffirm their confidence in its growth potential and strategic direction.</p>\n\n<p>Leading the bullish sentiment, Barclays analyst Peter Lawson raised the firm's price target on Syndax from $19 to $22, while maintaining an Overweight rating on the shares. This upgrade reflects growing optimism about the company's prospects. Similarly, Bank of America Securities analyst Jason Zemansky reiterated a Buy rating on Syndax Pharmaceuticals, further solidifying the positive outlook.</p>\n\n<p>Adding to the chorus of approval, H.C. Wainwright analyst Andres Y. Maldonado reaffirmed a Buy rating on Syndax with a price target of $40.00. This consistent positive feedback from multiple financial institutions suggests that investors are recognizing Syndax's potential for growth and success in the competitive pharmaceutical market. As the company continues to make strategic advancements, the market appears to be responding favorably to its long-term prospects.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Syndax Pharmaceuticals Soars 5.01% as Analysts Maintain Bullish Stance and Raise Price Targets</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Syndax Pharmaceuticals Soars 5.01% as Analysts Maintain Bullish Stance and Raise Price Targets\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-04 23:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Syndax Pharmaceuticals (SNDX) stock is soaring 5.01% in Tuesday's trading session, buoyed by a series of positive analyst reports and raised price targets. The biopharmaceutical company's shares are gaining momentum as Wall Street experts reaffirm their confidence in its growth potential and strategic direction.</p>\n\n<p>Leading the bullish sentiment, Barclays analyst Peter Lawson raised the firm's price target on Syndax from $19 to $22, while maintaining an Overweight rating on the shares. This upgrade reflects growing optimism about the company's prospects. Similarly, Bank of America Securities analyst Jason Zemansky reiterated a Buy rating on Syndax Pharmaceuticals, further solidifying the positive outlook.</p>\n\n<p>Adding to the chorus of approval, H.C. Wainwright analyst Andres Y. Maldonado reaffirmed a Buy rating on Syndax with a price target of $40.00. This consistent positive feedback from multiple financial institutions suggests that investors are recognizing Syndax's potential for growth and success in the competitive pharmaceutical market. As the company continues to make strategic advancements, the market appears to be responding favorably to its long-term prospects.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SNDX","symbol_name":"Syndax Pharmaceuticals, Inc. ","start_time":0,"source_url":"","article_id":"1168376862","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1168376862","pubTimestamp":1762270792,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Syndax Pharmaceuticals (SNDX) stock is soaring 5.01% in Tuesday's trading session, buoyed by a series of positive analyst reports and raised price targets. The biopharmaceutical company's shares are...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SNDX":"Syndax Pharmaceuticals, Inc. "},"translate_title":"个股追踪|Syndax Pharmaceuticals飙升5.01%分析师维持看涨立场并上调目标价","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNDX":1},"content_text":"Syndax Pharmaceuticals (SNDX) stock is soaring 5.01% in Tuesday's trading session, buoyed by a series of positive analyst reports and raised price targets. The biopharmaceutical company's shares are gaining momentum as Wall Street experts reaffirm their confidence in its growth potential and strategic direction.\nLeading the bullish sentiment, Barclays analyst Peter Lawson raised the firm's price target on Syndax from $19 to $22, while maintaining an Overweight rating on the shares. This upgrade reflects growing optimism about the company's prospects. Similarly, Bank of America Securities analyst Jason Zemansky reiterated a Buy rating on Syndax Pharmaceuticals, further solidifying the positive outlook.\nAdding to the chorus of approval, H.C. Wainwright analyst Andres Y. Maldonado reaffirmed a Buy rating on Syndax with a price target of $40.00. This consistent positive feedback from multiple financial institutions suggests that investors are recognizing Syndax's potential for growth and success in the competitive pharmaceutical market. As the company continues to make strategic advancements, the market appears to be responding favorably to its long-term prospects.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1168376862","isCrawlerRequest":true}